Candesartan versus placebo for migraine prevention in patients with episodic migraine: a randomised, triple-blind, placebo-controlled, phase 2 trial.
Øie LR, Wergeland T, Salvesen Ø, Gravdahl GRB, Aschehoug I, Gulati S, Bj Rk MH, Lundqvist C, Alstadhaug KBR, Winsvold BS, Aamodt AH, Larsen IC, B E MG, Braschinsky M, Müller B, Vetvik KGT, Müller KI, Aaseth K, Khanevski AN, Øvrevik AB, Vegrim HM, Lindroos J, Eid K, Engstrand H, Bezgal B, Larsen MB, Østhus JHG, Stovner LJ, Tronvik E.
Øie LR, et al.
Lancet Neurol. 2025 Oct;24(10):817-827. doi: 10.1016/S1474-4422(25)00269-8.
Lancet Neurol. 2025.
PMID: 40975098
Clinical Trial.